NeoGenomics, Inc. (NEO)

Market Cap	1.24B
Revenue (ttm)	660.57M
Net Income (ttm)	-78.73M
Shares Out	128.46M
EPS (ttm)	-0.62
PE Ratio	n/a
Forward PE	57.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,966,531
Open	9.42
Previous Close	9.48
Day's Range	9.04 - 9.68
52-Week Range	8.98 - 19.11
Beta	1.28
Analysts	Strong Buy
Price Target	19.78 (+105.61%)
Earnings Date	Apr 29, 2025

About NEO

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on d...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Nov 2, 1999
• Employees: 2,200
• Stock Exchange: NASDAQ
• Ticker Symbol: NEO
• Website: https://www.neogenomics.com

Financial Performance

In 2024, NeoGenomics's revenue was $660.57 million, an increase of 11.65% compared to the previous year's $591.64 million. Losses were -$78.73 million, -10.51% less than in 2023.

Analyst Forecast

According to 10 analysts, the average rating for NEO stock is "Strong Buy." The 12-month stock price forecast is $19.78, which is an increase of 105.61% from the latest price.

Price Target

$19.78

(105.61% upside)

Analyst Consensus: Strong Buy